Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

N/A

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07507318Phase 2Not Yet Recruiting

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Role: lead

NCT07502768Phase 1Not Yet Recruiting

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Role: lead

NCT06445803Phase 1Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Role: lead

NCT04366128Not ApplicableUnknown

Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL

Role: lead

NCT03079544Completed

Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients

Role: lead

NCT04004572Phase 2Unknown

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Role: lead

All 6 trials loaded